Apolizumab
From Wikipedia, the free encyclopedia
Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.[1][2]
[edit] References
- ^ Bayes M, Rabasseda X, Prous J (2003). "Gateways to clinical trials.". Methods Find Exp Clin Pharmacol 25 (9): 747–71. PMID 14685303.
- ^ Rech, J; Repp, R; Rech, D; Stockmeyer, B; Dechant, M; Niedobitek, G; Gramatzki, M; Valerius, T (2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.". Leukemia & lymphoma 47 (10): 2147–54. doi:10.1080/10428190600757944. PMID 17071489.
|
|
|
| Immune system ("-l(i[m])-") |
|
Human ("-limu-")
|
|
|
|
Mouse ("-limo-")
|
|
|
|
|
|
|
|
|
|
|
|
Chimeric + humanized
("-lixizu-")
|
|
|
|
| Interleukin ("-k(i[n])-") |
|
Human ("-kinu-")
|
|
|
|
Humanized ("-kizu-", "-kinzu-")
|
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
|
(what is this?) (verify)
